Last edition
News about "David Hung"
Nuvation Bio Gets US FDA sNDA Approval for IBTROZI
Nuvation Bio has announced US FDA approval of sNDA for IBTROZI (taletrectinib), updating duration of response in TKI-naïve ROS1-positive NSCLC.
David Hung | 19/09/2026 | By News Bureau
Nuvation Bio's Taletrectinib Advances UK Regulatory Review for ROS1-Positive Lung Cancer
The UK's MHRA has validated the marketing application for Nuvation Bio's taletrectinib, bringing the next-generation ROS1 inhibitor one step closer to approval for patients with advanced ROS1-positive non-small cell lung cancer in the UK.
David Hung | 01/07/2026 | By News Bureau | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy